Rat Urinary Bladder Carcinogenesis by Dual‐Acting PPAR α + γ Agonists
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Despite clinical promise, dual‐acting activators of PPAR α and γ (here termed PPAR α+γ agonists) have experienced high attrition rates in preclinical and early clinical development, due to toxicity. In some cases, discontinuation was due to carcinogenic effect in the rat urothelium, the epithelial layer lining the urinary bladder, ureters, and kidney pelvis. Chronic pharmacological activation of PPAR α is invariably associated with cancer in rats and mice. Chronic pharmacological activation of PPAR γ can in some cases also cause cancer in rats and mice. Urothelial cells coexpress PPAR α as well as PPAR γ, making it plausible that the urothelial carcinogenicity of PPAR α+γ agonists may be caused by receptor‐mediated effects (exaggerated pharmacology). Based on previously published mode of action data for the PPAR α+γ agonist ragaglitazar, and the available literature about the role of PPAR α and γ in rodent carcinogenesis, we propose a mode of action hypothesis for the carcinogenic effect of PPAR α+γ agonists in the rat urothelium, which combines receptor‐mediated and off‐target cytotoxic effects. The proposed mode of action hypothesis is being explored in our laboratories, towards understanding the human relevance of the rat cancer findings, and developing rapid in vitro or short‐term in vivo screening approaches to faciliate development of new dual‐acting PPAR agonist compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nongenomic actions of steroid hormones
Lösel, R., & Wehling, M. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1009 · Cited by 980 · cited 1×
“The mechanisms for the nongenomic actions of PPAR agonists are unknown, but may have parallels in, for example, the nongenomic actions of steroid hormones [99].”
BackgroundSafety issues and prospects for future generations of PPAR modulators
RUBENSTRUNK, A., HANF, R., HUM, D., FRUCHART, J., & STAELS, B. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.003 · Cited by 309 · cited 7×
“These 6 developmental PPARα+γ agonists represent different nonthiazolidinedione chemical structures, with different balances between PPARα and γ activation [3, 5, 7, 11].”
BackgroundInfluentialKim, M. S., Sweeney, T. R., Shigenaga, J. K., Chui, L. G., Moser, A., Grunfeld, C., & Feingold, K. R. (2007) · Metabolism · doi:10.1016/j.metabol.2006.10.007 · Cited by 168
Mensink, M., Hesselink, M. K. C., Russell, A. P., Schaart, G., Sels, J.-P., & Schrauwen, P. (2007) · International Journal of Obesity · doi:10.1038/sj.ijo.0803567 · Cited by 160 · cited 1×
“Further, it has been described that PPARα and PPARγ agonists may exhibit synergistic effects in cells coexpressing PPARα and PPARγ [19, 28, 53–55].”
BackgroundPPARγ as a therapeutic target for tumor angiogenesis and metastasis
Panigraphy, D., Huang, S., Kieran, M. W., & Kaipainen, A. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.7.2014 · Cited by 137 · cited 3×
“We have a different interpretation of the available data: it is clear that activation of PPARα can cause tumours in rats and mice (Table 1) [9], and while more controversial, activation of PPARγ can at least in some cases cause cancer in rats and mice (Table 1) [5, 6, 8, 34, 36].”
BackgroundClay, C. E., Namen, A. M., Atsumi, G.-I., Trimboli, A. J., Fonteh, A. N., High, K. P., & Chilton, F. H. (2001) · Journal of Investigative Medicine · doi:10.2310/6650.2001.33786 · Cited by 67
Cited by
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60953-3 · Cited by 1,393
Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes
Lewis, J. D., Habel, L. A., Quesenberry, C. P., Strom, B. L., Peng, T., Hedderson, M. M., Ehrlich, S. F., Mamtani, R., Bilker, W., Vaughn, D. J., et al. (2015) · JAMA · doi:10.1001/jama.2015.7996 · Cited by 320
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Cheng, H. S., Tan, W. R., Low, Z. S., Marvalim, C., Lee, J. Y. H., & Tan, N. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205055 · Cited by 264
Pioglitazone use and risk of bladder cancer: Population based cohort study
Tuccori, M., Filion, K. B., Yin, H., Yu, O. H., Platt, R. W., & Azoulay, L. (2016) · BMJ · doi:10.1136/bmj.i1541 · Cited by 237
Hong, F., Xu, P., & Zhai, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082189 · Cited by 139
Metadata
- Authors
- Oleksiewicz, M. B., Southgate, J., Iversen, L., & Egerod, F. L.
- Venue
- PPAR Research
- Publisher
- Wiley
- Published
- 2008-01
- Volume
- 2008
- Issue
- 1
- Pages
- 103167-103167
- ISSN
- 1687-4757 (ISSN-L)
- 1687-4765
- OpenAlex
- W2059083569
- Cited by
- 40
- References
- 6
- FWCI
- 0.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rat Urinary Bladder Carcinogenesis by Dual‐Acting PPAR α + γ Agonists. https://app.cochat.ai/papers/10.1155/2008/103167
- The paper
- Oleksiewicz, M. B., Southgate, J., Iversen, L., & Egerod, F. L. (2008). Rat Urinary Bladder Carcinogenesis by Dual‐Acting PPAR α + γ Agonists. PPAR Research. https://doi.org/10.1155/2008/103167
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.